法律意见书 地址：青岛市市南区香港中路 8 号青岛中心大厦 45 层 电话：(0532) 55769077 传真：(0532) 55769155 邮编：266071 上海锦天城（青岛）律师事务所 法律意见书 上海锦天城（青岛）律师事务所 上海锦天城（青岛）律师事务所 关于蓝帆医疗股份有限公司 2025 年第六次临时股东会的 关于蓝帆医疗股份有限公司 2025 年第六次临时股东会的 法律意见书 致蓝帆医疗股份有限公司： 上海锦天城（青岛）律师事务所（以下简称"本所"）接受蓝帆医疗股份 有限公司（以下简称"公司"或"蓝帆医疗"）的委托，指派靳如悦、张晓敏 律师出席了公司于 2025 年 12 月 15 日召开的 2025 年第六次临时股东会（以下 简称"本次股东会"）。现根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）和《上 市公司股东会规则》（以下简称"《股东会规则》"）、《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、 规范性文件以及《蓝帆医疗股份有限公司章程》（以下简称"《公司章程》"） 的规定，对本次股 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-111 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 2025年第六次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、为尊重中小投资者利益，提高中小投资者对公司股东会决议的重大事项参与度， 本次股东会审议议案对中小投资者单独计票。中小投资者是指除上市公司董事、高级 管理人员以及单独或合计持有上市公司5%以上股份的股东以外的其他股东。 2、本次股东会未出现否决议案的情形。 3、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议的通知：蓝帆医疗股份有限公司（以下简称"公司"）于2025年11月29日 在《中国证券报》、《上海证券报》、《证券时报》、《证券日报》和巨潮资讯网 （http://www.cninfo.com.cn）上刊登了会议通知。 2、会议召开的日期、时间： （1）现场会议时间：2025 年 12 月 15 日（星期 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-112 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 第六届董事会第三十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 综上所述，根据《蓝帆医疗股份有限公司公开发行可转换公司债券募集说明书》 相关规定及公司 2025 年第六次临时股东会的授权，综合考虑公司未来发展前景及股票 价格走势等因素，董事会决定"蓝帆转债"的转股价格向下修正为 9.50 元/股，修正后 的转股价格自 2025 年 12 月 16 日起生效。自 2025 年 12 月 16 日之后，若"蓝帆转债" 再次触发转股价格向下修正条款，届时公司董事会将再次召开会议决定是否行使"蓝 帆转债"转股价格向下修正权利。 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 具体内容详见刊登于公司指定的信息披露媒体《中国证券报》、《上海证券报》、《证 券时报》、《证券日报》和巨潮资讯网（http://www ...

蓝帆医疗公告，修正"蓝帆转债"转股价格至9.5元/股，修正后的转股价格自2025年12月16日起生效。 ...

Core Viewpoint - The A-share market shows a mixed performance with the Shanghai Composite Index closing at 3867.92 points, slightly down by 0.55%, while the total trading volume reached 1.794 trillion yuan, indicating active market participation [1]. Group 1: Market Performance - The Shanghai Composite Index closed above the annual line, reflecting a stable market condition despite a minor decline [1]. - A total of 101 A-shares have surpassed the annual line, indicating a positive trend for these stocks [1]. Group 2: Notable Stocks - The stocks with the largest deviation from the annual line include: - Junyao Health (均瑶健康) with a deviation rate of 8.59% and a daily increase of 10.04% [1]. - Aerospace Information (航天信息) with a deviation rate of 7.93% and a daily increase of 10.00% [1]. - Guangbai Co. (广百股份) with a deviation rate of 7.58% and a daily increase of 9.96% [1]. - Stocks with smaller deviations that have just crossed the annual line include: - Shunbo Alloy (顺博合金) and Shenzhen Airport (深圳机场), indicating a cautious upward movement [1]. Group 3: Trading Data - The total trading volume for A-shares today was 1.794 trillion yuan, reflecting significant market activity [1]. - The trading turnover rates for notable stocks varied, with Junyao Health at 3.60% and Aerospace Information at 4.93%, indicating investor interest [1].

证券之星消息，蓝帆医疗(002382)12月15日在投资者关系平台上答复投资者关心的问题。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 投资者提问：经查，蓝帆医疗新品血管内冲击波治疗仪在招标网上中标数量明显少于其他同期获批的友 商产品，请问，造成上述问题的原因是公司销售力量比较单薄还是因为产品的竞争力缺陷的问题？ 蓝帆医疗回复：您好，经公司了解，目前血管内冲击波治疗仪尚无官方公开的完整招标及中标数量数 据。您所查阅到的信息可能来源于个别医院所发布基于其自身采购的中标结果，并不代表整体市场情 况。公司自主研发的一次性使用冠脉血管内冲击波导管—SoniCracker-CL 是国内首批上市的国产冠脉血 管内冲击波导管之一，也是目前国内规格型号最齐全的冲击波导管，搭配公司自主研发的冠脉血管内冲 击波治疗设备，组成SoniCracker冲击波治疗系统。该系统采用了升级的输送系统及球囊体设计，大幅度 提升了产品的操作性能。同时，基于原创专利电极设计，确保了产品工作时能够释放高强度且均匀的声 波能量，使其治疗效果较同类型产品更加稳定。自202 ...

Core Viewpoint - The company, Blue Sail Medical, is enhancing its competitiveness in the nitrile glove market through strategic investments and acquisitions, including a significant capital injection from a Thai industrial investor, HKG, amounting to $200 million (approximately 1.42 billion RMB) [1][2][3]. Group 1: Investment and Acquisitions - HKG has completed the full payment of $200 million for its investment in the joint venture, Shandong Blue Sail Health Technology Co., Ltd., with plans to use 800 million RMB to acquire 100% equity in two subsidiaries related to nitrile gloves and 400 million RMB to acquire 80% equity in Hongda Thermal Power Co., Ltd. [1][2] - The investment aims to revitalize the company's nitrile glove business and improve operational efficiency amid changing international trade conditions [1][4]. Group 2: Strategic Goals and Market Positioning - The acquisitions are part of Blue Sail Medical's strategy to become one of the most cost-effective glove manufacturing bases globally, leveraging external investment to enhance competitiveness [2][3]. - The company aims to integrate its nitrile glove production bases to improve coordination in production plans and supply chain stability, which is essential for scaling and intensifying production [4][7]. Group 3: Energy Supply and Cost Management - Energy costs are a significant factor in nitrile glove production, accounting for approximately 15% to 25% of total costs. The acquisition of Hongda Thermal Power will introduce a "cogeneration" model to reduce energy costs [5][6]. - The establishment of dual thermal power plants in Shandong will address previous energy supply shortcomings and decrease reliance on external energy sources [5][6]. Group 4: Global Trade and Competitive Strategy - The collaboration with HKG is a response to the evolving global trade landscape and aligns with China's Belt and Road Initiative, aiming to enhance international cooperation and market presence [7][8]. - The company is focused on exporting technology, brand, and standards to strengthen its position in the global market, which is crucial for high-quality development in the face of trade uncertainties [7][8].

Group 1 - The core point of the article is that Bluestar Medical announced plans to use up to 1.1 billion yuan of idle self-owned funds to purchase high-safety, liquid financial institution wealth management products, with the funds being available for rolling use within a 12-month period from the board's approval [1] Group 2 - The investment is aimed at enhancing the company's financial management and optimizing the use of idle funds [1] - The decision reflects the company's strategy to ensure liquidity while seeking safer investment options [1] - The board's approval is a key step in executing this financial strategy, indicating proactive management of resources [1]

Group 1 - The company and its subsidiaries will conduct related transactions based on principles of honesty, fairness, and market pricing, ensuring the fairness of these transactions [1][9] - The company plans to purchase raw materials from Langhui Petrochemical, which is a major supplier of plasticizers and resin, providing advantages in cost and supply stability [1][2] - The independent directors have approved the related transactions for 2026, confirming that these will not affect the company's independence or financial status [3][4] Group 2 - The company has signed a 13-year lease agreement for office space and parking with Zibo Henghui, with a rental fee of 600,000 RMB per year for the first five years, and market-based adjustments thereafter [5][10] - The company intends to continue leasing the property at the same rate after the initial five-year period, ensuring operational convenience and cost-effectiveness [11][12] - The total amount of related transactions with the mentioned parties has reached approximately 627.87 million RMB as of the announcement date [13] Group 3 - The company plans to apply for a total credit limit of up to 3 billion RMB for 2026, which includes various financial instruments to support its operations [18][19] - The company will provide guarantees for subsidiaries based on their financial health, with a maximum of 2 billion RMB for those with a debt ratio above 70% [19][25] - The company has no overdue guarantees or legal issues related to its guarantees as of the announcement date [26] Group 4 - The company intends to invest up to 1.1 billion RMB in high-security, liquid financial products to enhance fund utilization and returns [30][31] - The investment will be made using idle funds, ensuring that normal operations are not affected [38] - The company has established risk control measures for these investments, including regular audits and strict selection of investment targets [37][54] Group 5 - The company plans to engage in financial derivatives trading to hedge against currency and interest rate risks, with a maximum margin and contract value set for 2026 [41][44] - The trading will be conducted with qualified financial institutions, ensuring compliance with regulations [46][49] - The company has outlined risk management strategies to mitigate potential market, liquidity, and operational risks associated with these transactions [50][54] Group 6 - The company has approved a budget of up to 5 million RMB for charitable donations in 2026, reflecting its commitment to social responsibility [59][60] - The donations will be funded from the company's own resources and will not adversely impact its operations [61] Group 7 - The company has proposed to purchase liability insurance for its directors and senior management to enhance risk management [63][64] - The insurance coverage will have a limit of up to 100 million RMB, with an annual premium not exceeding 400,000 RMB [64]

（文章来源：证券日报） 证券日报网讯 12月12日晚间，蓝帆医疗发布公告称，2025年12月12日，公司召开了第六届董事会第三 十五次会议，审议并通过了《关于2026年度申请授信及担保额度预计的议案》。根据2026年度整体生产 经营、资金需求及融资情况，公司及子公司2026年度拟向银行等金融机构申请综合授信总额不超过人民 币30亿元，授信品种包括但不限于流动资金贷款、保函、银行承兑汇票、国内信用证、国内保理、融资 租赁等综合授信业务，具体融资金额将视公司及子公司生产运营对资金的需求来确定。公司及子公司将 根据金融机构的授信要求为上述综合授信提供担保额度总计不超过人民币30亿元，担保方式包括但不限 于连带责任担保、股权质押、资产抵押、信用担保、保证担保等方式。其中，预计为公司及资产负债率 70%以下（不含70%）的子公司提供的担保额度不超过人民币28亿元，预计为资产负债率70%以上（含 70%）的子公司提供的担保额度不超过人民币2亿元。上述担保额度包括新增担保及原有担保展期或续 保。 ...